Overcoming resistance in chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1785-1793

  Cooper, Susannah ^a   Giles, Francis J ^b   Savona, Michael R ^a,b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Chemotherapeutic approaches; Leukemic progenitor cells; Myeloid leukemias and dysplasias; Pharmacotherapeutics; Signaling therapies; Stem and primitive progenitor cells

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG INHIBITION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW;

BENZAMIDES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 71049186807     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903267559     Document Type: Review

References (74)

1. Nowell. A minute chromosome in human chronic granulocytic leukemia. Science 1960;142:1497.
2. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:125-130.
3. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-280.
4. Karbasian Esfahani M, Morris EL, Dutcher JP, Wiernik PH. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol 2006;7:189-199.
5. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
6. Champlin R, Ho W, Arenson E, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 1982;60:1038-1041.
7. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-4077.
8. Silver RT, Peterson BL, Szatrowski TP, et al. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma 2003;44:39-48.
9. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
11. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054-1061.
12. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698.
13. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926-935.
14. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283.
15. Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006;103:9244-9249.
16. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
17. Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007;6:1400-1405.
18. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551. (Pubitemid 43882350)
19. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541. (Pubitemid 43882349)
20. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-2338.
21. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53-55.
22. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987-7990.
23. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007;92:1238-1241.
24. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinibresistant BCR-ABL mutations including T315I. Blood 2008;111:4355-4364.
25. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-502.
26. Paquette RL, Sawyers CL. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood (Suppl) 2007;110:1030(Abstract).
27. Cortes J, Paquette R, Talpaz M et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Pht leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 2008;112:3232(Abstract).
28. Rivera V, Xu Q, Wang F, et al. Potent antitumor activity of AP24534, an orally acitve inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia. Blood (Suppl) 2007;110:1032(Abstract).
29. O'Hare T, Eide CA, Tyner JW, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA 2008;105:5507-5512.
30. Tanaka R, Squires M, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283 on imatinib-resistant CML models. Blood 2008;112;403a.
31. Nawrocki S, Medina E, Smith S, et al. The aurora kinase inhibitor MLN8237 has potent anticancer activity in CML and Pht ALL models and significantly increases the efficacy of nilotinib. Blood 2008;112:1097a.
32. Van Etten R, Chan W, Zaleskas V, et al. A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood (Suppl) 2007;110:463(Abstract).
33. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005;15:34-41.
34. Janssens V, Van Hoof C, Merlevede W, Goris J. PTPA regulating PP2A as a dual specificity phosphatase. Methods Mol Biol 1998;93:103-115.
35. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABLregulated SET protein. Cancer Cell 2005;8:355-368.
36. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-2421.
37. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006;95:775-781.
38. Mansoor M, Melendez AJ. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. Rev Recent Clin Trials 2008; 3:62-69.
39. Tedesco-Silva H, Szakaly P, Shoker A, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: sixmonth results of a double-blind study. Transplantation 2007; 84:885-892.
40. Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273-24278.
41. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319-327.
42. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-252.
43. Trachootham D, Zhang H, Zhang W. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redoxmediated mechanism. Blood 2008;112:1912-1922.
44. Duvoix A, Morceau F, Delhalle S, et al. Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem Pharmacol 2003;66:1475-1483.
45. Duvoix A, Morceau F, Schnekenburger M, et al. Curcumininduced cell death in two leukemia cell lines: K562 and Jurkat. Ann N Y Acad Sci 2003;1010:389-392.
46. Wu LX, Xu JH, Huang XW, Zhang KZ, Wen CX, Chen YZ. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacol Sin 2006;27:694-699.
47. Wu LX, Xu JH, Wu GH, Chen YZ. Inhibitory effect of curcumin on proliferation of K562 cells involves downregulation of p210(bcr/abl) initiated Ras signal transduction pathway. Acta Pharmacol Sin 2003;24:1155-1160.
48. William BM, Goodrich A, Peng C, Li S. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia. Hematology 2008; 13:333-343.
49. Mizuchi D, Kurosu T, Kida A, et al. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. Biochem Biophys Res Commun 2005; 326:645-651.
50. Salomoni P, Wasik MA, Riedel RF, et al. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation- deficient BCR/ABL mutant. J Exp Med 1998;187:1995-2007.
51. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843-2853.
52. Miyamoto N, Sugita K, Goi K, et al. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 2001;15:1758-1768.
53. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006;66:6468-6472. (Pubitemid 44085597)
54. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-758.
55. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogenstimulated and transformed cells. Cancer Res 2000;60:3504-3513.
56. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716-5722.
57. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-2762.
58. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165-5173.
59. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107:1149-1155.
60. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110:678-685.
61. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-5552.
62. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105:1768-1776.
63. Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-1206.
64. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-5135.
65. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-1893.
66. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid downregulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005;15: 169-172.
67. Khoury H, Michallet M, Corm S. Safety and efficacy study of subcutaneous homoharringtonine (SC HHT) in imatinibresistant chronic myeloid leukemia with the T315I mutation; initial report of a phase II trial. Blood (Suppl) 2007;110: 1050(Abstract).
68. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/ablthuman leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007;72:788-795.
69. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res 2007;13:4280-4290.
70. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-779.
71. Van Etten R CW, Zaleskas V, et al. Switch pocket inhibitors of teh ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and Blymphoblastic leukemia induced by BCR-ABL T315I. Blood 2008;112:216a.
72. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS- 354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539.
73. Sharma SV, Fischbach MA, Haber DA, Settleman J. 'Oncogenic shock': explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006;12: 4392s-4395s.
74. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008;8:341-350.